Volume 2.00 | Jan 4

Hematopoiesis News 2.00, January 4, 2011.  
In this issue: Science News  |   Current Publications  |   Industry News  |   Policy News  |   Events Subscribe   |  Unsubscribe

TOP STORY

NIH Scientists Identify Possible Gene Target for Treating a Form of Lymphoma 
MYD88 encodes a protein that is crucial for the normal immune response to invading microorganisms. New experiments show a mutation in the MYD88 protein sequence can cause uncontrolled cellular signaling, leading to survival of malignant cells. [Press release from the National Institutes of Health discussing online prepublication in Nature]

ProficiencyTesting_v01_645x110-Video


SPECIAL FEATURE

Facebook Cell Therapy News is now on Facebook! Join us.

Twitter Follow us on Twitter! @Hema_News

Interested in recruiting talented individuals? Post your career opportunities in Hematopoiesis News at no cost. Contact us at [email protected]



SCIENCE NEWS

New Evidence of Stem Cells’ Pivotal Role in Cancer Shown in Study
Leukemia patients whose cancers express higher levels of genes associated with cancer stem cells have a significantly poorer prognosis than patients with lower levels of the genes, say researchers. [Press release from the Stanford University School of Medicine discussing online prepublication in the Journal of the American Medical Association]

CAS_645x110_v01


CURRENT PUBLICATIONS  (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Association of a Leukemic Stem Cell Gene Expression Signature with Clinical Outcomes in Acute Myeloid Leukemia
The purpose of this study was to identify an leukemic stem cell gene expression signature and test its association with clinical outcomes in acute myeloid leukemia. [JAMA]

Evi-1 Is a Transcriptional Target of MLL Oncoproteins in Hematopoietic Stem Cells
In this study, researchers found that ecotropic viral integration site-1 (Evi-1) is frequently up-regulated in bone marrow cells transformed by MLL-ENL or MLL-AF9. [Blood]

Rara Haploinsufficiency Modestly Influences the Phenotype of Acute Promyelocytic Leukemia in Mice
The data show that Rara haploinsufficiency (like Pml haploinsufficiency and RARA-PML) can cooperate with RARA-PML to influence the pathogenesis of acute promyelocytic leukemia in mice, but that PML-RARA is the t(15;17) disease-initiating mutation. [ Blood]

Janus Kinase 2 Regulates Bcr-Abl Signaling in Chronic Myeloid Leukemia
Despite the success of imatinib mesylate (IM) in the early chronic phase of chronic myeloid leukemia (CML), patients are resistant to IM and other kinase inhibitors in the later stages of CML. The findings indicate that inhibition of Janus kinase 2 (Jak2) in Bcr-Abl+ cells overcomes imatinib mesylate resistance although the precise mechanism of Jak2 action is unknown. [Leukemia]

Heart Failure-Associated Anemia: Bone Marrow Dysfunction and Response to Erythropoietin
Results suggest that bone marrow dysfunction is an important contributor to heart failure (HF)-associated anemia and that erythropoietin is not an effective agent to treat HF-associated anemia. [J Mol Med]

CLINICAL RESEARCH

Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients with Lymphoma
High-dose chemotherapy with peripheral blood progenitor cell autograft is effective in high-risk lymphoma, particularly with the addition of rituximab; however, it is associated with risk of secondary malignancy. These issues have been addressed in a series of 1,347 patients with lymphoma treated with a high-dose sequential program. [J Clin Oncol]

Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
Based on encouraging reports of lenalidomide in relapsed and refractory chronic lymphocytic leukemia (CLL), researchers investigated the first-line use of single-agent lenalidomide in CLL. [J Clin Oncol]

A Randomized Comparison of Four Courses of Standard-Dose Multiagent Chemotherapy Versus Three Courses of High-Dose Cytarabine Alone in Post-Remission Therapy for Acute Myeloid Leukemia in Adults: The JALSG AML201 Study
Researchers conducted a prospective randomized study to assess the optimal post-remission therapy for adult acute myeloid leukemia of age less than 65 in the first complete remission. [Blood]


INDUSTRY NEWS

Veridex, LLC Announces Collaboration to Develop Next-Generation Circulating Tumor Cell (CTC) Technology with Massachusetts General Hospital
Veridex, LLC announced a collaboration with Massachusetts General Hospital to develop and commercialize a next-generation circulating tumor cell technology for capturing, counting and characterizing tumor cells found in patients’ blood. [Johnson & Johnson Press Release]

Alexion Eyes FDA OK After Two-Phase Tests
Alexion Pharmaceuticals is in the unusual position of being poised to get a new drug approval based on phase two test results, not the typical three. [Investor’s Business Daily]




Learn more about Hematopoiesis News: Archives  |   Events  |   Subscribe  |   Contact Us